AstraZeneca plc Stock (GB0009895292): Jefferies sticks with Buy rating and 18,000p target

Jefferies reaffirmed its Buy rating and 18,000 pence price target on AstraZeneca, highlighting the pharma group as a rare European large cap with credible premium growth potential into the next decade.

Responsible: ad hoc news Stocks & Analysis Desk. Reviewed prior to publication on June 16, 2026 at 5:23 PM ET. Details in the imprint.

Jefferies is reiterating its positive stance on AstraZeneca plc on June 16, 2026, keeping a Buy rating and a price target of 18,000 pence (GBP 180) for the London-listed pharma heavyweight. According to the latest dpa-AFX summary of the research note, analyst Michael Leuchten positions AstraZeneca as the only major European pharma group that can credibly promise premium growth at least through 2030, pointing to the pipeline as a key differentiator. As of late morning trading in London on the same day, AstraZeneca shares changed hands at around 132.10 GBP, putting the Jefferies target meaningfully above the current spot price. In terms of share price dynamics, the stock has traded relatively steadily so far this year, with MarketBeat data showing a level of about 137.90 GBP at the start of 2026 versus roughly 132 to 133 GBP in mid-June, a decline in the low single-digit percentage range.

Jefferies reaffirms Buy call and double-digit upside case

The latest Jefferies report keeps AstraZeneca at Buy with an unchanged target price of 18,000 pence, implying material upside from the current London quote. With the stock reported around 132.10 GBP in London trading on June 16, 2026, the Jefferies target corresponds to an upside potential in the range of roughly 35 percent from that intraday level, underlining the broker's constructive risk-reward view. The note summarized by dpa-AFX states that AstraZeneca is seen as the only European large-cap pharma name with a credible case for "premium growth" at least until 2030, a phrase that highlights the bank's conviction in the durability of the company's above-market expansion prospects. Jefferies attributes this view primarily to the breadth and maturity of AstraZeneca's late-stage pipeline and key growth franchises, suggesting that the company can extend its current momentum over multiple planning cycles.

In the research commentary, analyst Michael Leuchten emphasizes that upcoming clinical milestones could provide further catalysts, with the AVANZAR lung cancer study identified as the next key driver for the stock. The AVANZAR program belongs to AstraZeneca's oncology portfolio, an area that has been central to its strategic focus and capital allocation in recent years. Jefferies' optimistic stance on AVANZAR signals confidence that the trial could deliver data supportive of broader uptake or new indications in lung cancer, a tumor type that remains a core battleground for global biopharma companies. If the study reads out positively, Jefferies expects that it might serve as an inflection point in how investors value AstraZeneca's longer-term earnings power in oncology.

Beyond AVANZAR, Jefferies' Buy rating sits against a backdrop of already robust analyst coverage. MarketBeat data for the London-listed AstraZeneca security shows a consensus price target in the area of 153.33 GBP, equating to a mid-teens percentage upside versus a current price around 132 GBP. That consensus level is lower than the Jefferies 180 GBP target, placing the US brokerage on the more bullish end of the spectrum. The gap between the consensus and the Jefferies target implies that the bank is assigning greater weight to high-conviction growth drivers such as late-stage oncology and rare disease assets, as well as potential margin expansion from pipeline maturation.

The dpa-AFX summary also notes that Jefferies regards AstraZeneca's growth outlook as comparatively dependable within European pharma, suggesting that the company's diversification across oncology, cardiovascular, renal and metabolism (CVRM), respiratory and rare disease can help smooth volatility across therapeutic areas. This diversified approach is visible in the company's product mix and pipeline disclosures on its own investor relations pages, where it highlights oncology and CVRM as key revenue engines over the coming years. Jefferies' use of the term "premium growth" implicitly contrasts AstraZeneca with peers whose near-term earnings profiles tilt more heavily toward established blockbuster franchises facing patent expiries. For AstraZeneca, the analyst sees a stronger balance between existing cash-generative brands and emergent drugs still early in their commercial lifecycle.

From a US perspective, AstraZeneca shares also trade in New York under the ticker AZN, providing dollar-denominated access to the same underlying business for investors on the NYSE. A snapshot from Pluang's AZN overview shows the US-listed shares around $178.75 at the time of the latest update, reflecting a day-on-day decline of about 1.94 percent accompanied by what the platform characterizes as a bearish technical signal from moving averages. While the precise time stamp of that quote relates to the US market, it underscores that sentiment on the stock can diverge over short intervals between trading venues, even though the long-term fundamental drivers assessed by Jefferies apply across listings. For investors comparing London and New York quotes, currency effects and ADR ratios need to be considered when mapping pound-denominated targets such as the 18,000 pence level to US dollar equivalents.

How AstraZeneca's growth narrative compares with sector peers

Jefferies' framing of AstraZeneca as a standout among European large-cap pharmas implicitly raises the question of how its growth profile stacks up against peers. According to MarketBeat, AstraZeneca's London-listed shares carry a consensus target of about 153.33 GBP versus a recent price around 132.82 GBP, pointing to expected upside of roughly 16 percent on average across covering analysts. That level of implied upside is relatively robust in a sector often characterized by modest single-digit growth projections and heavy reliance on established franchises. Jefferies' 180 GBP target sits meaningfully above this average, reinforcing the impression that the firm views AstraZeneca as capable of sustaining higher revenue and earnings growth than the typical European pharma incumbent.

One factor underpinning this confidence is AstraZeneca's strong footing in oncology, a therapeutic area that has attracted intense R&D investment and strategic focus across the global industry. The company's oncology portfolio includes targeted therapies and immuno-oncology products aimed at several tumor types, with lung cancer being a particularly important commercial segment. Jefferies' highlighting of the AVANZAR lung cancer study as the "next share price driver" suggests that the firm sees the potential for incremental value creation from new data in this high-priority area. By contrast, some European peers remain more dependent on mature primary-care portfolios or face nearer-term patent cliffs, potentially constraining their ability to deliver sustained "premium growth" through 2030 without significant pipeline surprises.

AstraZeneca's rare disease business also contributes to the forward growth narrative, particularly through Alexion, the company's dedicated rare disease unit formed after the acquisition of Alexion Pharmaceuticals. Recent industry updates highlight that Alexion has secured a priority review from the US Food and Drug Administration for a supplemental Biologics License Application (sBLA), reinforcing the momentum in its rare disease franchise. While the specific sBLA mentioned in sector news flows is part of a broader pharma round-up and not tied solely to the Jefferies note, it illustrates the dynamic regulatory environment in which AstraZeneca is operating. For Jefferies, such regulatory milestones can support the thesis that AstraZeneca has multiple shots on goal across its pipeline, which, combined with oncology advances such as AVANZAR, underpin the bank's conviction on long-term growth.

The company's R&D and manufacturing investments also play a role in how the market views its strategic positioning. A NYSE communication celebrating AstraZeneca highlighted a major cell therapy facility in Montgomery County, described as a $300 million investment expected to create more than 150 jobs while advancing cancer research and treatment capabilities. Although this facility news was disseminated earlier and is not directly tied to the June 16 Jefferies rating update, it illustrates the scale of AstraZeneca's capital deployment into cutting-edge modalities such as cell therapy. Such long-term infrastructure projects are consistent with an ambition to remain at the forefront of oncology innovation, a key pillar of the growth story Jefferies is effectively endorsing with its Buy rating and extended time horizon.

Notwithstanding its constructive view, Jefferies' report does not eliminate the typical risks associated with large-cap pharma investing, including clinical trial setbacks, regulatory uncertainties and competitive pressures. In oncology, for example, AstraZeneca faces well-financed rivals pursuing overlapping indications in lung cancer and other tumor types, increasing the stakes for pivotal readouts like AVANZAR. Similarly, in rare diseases, regulatory standards and payer scrutiny are evolving, which can affect pricing power and market access for high-cost therapies. Jefferies' decision to maintain a Buy rating despite these headwinds indicates that, in its assessment, the probability-weighted pipeline value and current portfolio strength outweigh the sector's structural challenges at the prevailing valuation.

For US retail investors, another practical consideration is the dual nature of AstraZeneca's listing, with the primary quote in London and American depositary shares in New York. Currency fluctuations between the British pound and the US dollar, as well as differences in local investor bases and index inclusion, can influence how quickly sentiment shifts in one market echo in the other. As per MarketBeat, the stock's performance since the beginning of 2026 has been modestly negative in local currency terms, with a decline of about 3.7 percent from 137.90 GBP at the start of the year to around 132.82 GBP in mid-June. That backdrop of muted year-to-date performance provides context for why Jefferies can argue that the current price does not fully reflect its longer-term growth expectations, even as some shorter-term technical indicators, such as those quoted by Pluang, point to near-term caution.

Overall, the latest Jefferies reiteration underscores that AstraZeneca remains firmly on the radar of major sell-side institutions as a core European pharma name with above-average growth prospects. The combination of a sizable implied upside to the 18,000 pence target, a portfolio anchored in oncology and rare diseases, and the identification of specific near-term catalysts such as the AVANZAR lung cancer study forms the backbone of the current Buy case. Investors watching the stock may want to monitor upcoming clinical and regulatory milestones, as well as any shifts in consensus estimates, to gauge whether the fundamental narrative continues to track the bullish assumptions embedded in Jefferies' valuation. As always, individual decisions will depend on risk tolerance, portfolio construction and views on broader sector dynamics, particularly in areas like oncology competition and drug pricing.

Key facts on the AstraZeneca stock

• Name: AstraZeneca plc
• Industry: Pharmaceuticals and biotechnology
• Headquarters: Cambridge, United Kingdom
• Core markets: Global presence with key markets in Europe, the United States and emerging markets
• Revenue drivers: Oncology, cardiovascular, renal and metabolism (CVRM), respiratory and rare disease therapies
• Listing: Primary listing on London Stock Exchange (ticker: AZN); secondary listing on Nasdaq Stockholm; American depositary shares traded on NYSE (ticker: AZN)
• Trading currency: British pound (GBP) in London; US dollar (USD) for NYSE-listed ADS

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.